OncoSec Medical Inc (ONCSQ)

[chickpea598]

I think 50% would be a fair assumption. One other thing about the 64%-75% previous data. That data is from the long-term melanoma phase II study with a subset of patients that went on to receive Keytruda. According to Oncosec IR department those patients were not screened with the biomarker assay, which means they may or may not have been non-responders to keytruda monotherapy. So we will only know for sure if we are seeing above average response rates when data is released on Nov. 12th. I think 50% would be a good solid guess though based on previous data and that would be significant indeed.